Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10736550 | 0.95 | CYP4F2 (0.64) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL432816 | 0.95 | CYP4F2 (0.64) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL1239542 | 0.90 | ALOX5 (0.65) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL68902 | 0.89 | CYP4F2 (0.85) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL7999711 | 0.89 | ALOX5 (0.59) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL10763604 | 0.87 | F2RL1 (0.73) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL19457413 | 0.87 | MAPT (0.56) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL3675681 | 0.87 | ALOX5 (0.57) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL275760 | 0.87 | F2RL1 (0.58) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 | |
| SCHEMBL15164347 | 0.86 | F2RL1 (0.62) | CYP4F2CYP4A11MAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2025-08-26 | — | — | US | disclosed |
| US-20220298097-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-111087306-B | Method for preparing organic carboxylic ester by aryl bidentate phosphine ligand combined catalysis | 南京诚志清洁能源有限公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021129138-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY MEANS OF COMBINATORIAL CATALYSIS WITH ARYL BIDENTATE PHOSPHINE LIGAND | 南京诚志清洁能源有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021129138-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY MEANS OF COMBINATORIAL CATALYSIS WITH ARYL BIDENTATE PHOSPHINE LIGAND | 南京诚志清洁能源有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-111087306-A | Method for preparing organic carboxylic ester by aryl bidentate phosphine ligand combined catalysis | 南京诚志清洁能源有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108473612-A | The manufacturing method of solid catalyst component for olefin polymerization, polymerization of olefines catalyst and olefin polymer | 东邦钛株式会社 | 2018-08-31 | — | — | CN | disclosed |
| EP-1583738-B1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| EP-1583738-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GmbH (DE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063148-A1 | INDENONCARBOXYLIC ACIDS DERIVATIVES AND THEIR USE FOR THE TREATMENT OF AND PREVENTING DIABETES AND DYSLIPIDAEMIA | MERCK PATENT GMBH (DE) | 2004-07-29 | — | — | WO | disclosed |
| EP-0325245-B1 | Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use | TANABE SEIYAKU CO (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4948810-A | PLATELET AGGREGATION INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
| EP-0325245-A1 | Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use | TANABE SEIYAKU CO., LTD. (JP) | 1989-07-26 | — | — | EP | disclosed |
| EP-0120304-A2 | Substituted 4,10-dihydro-10-oxothieno benzoxepins and intermediates thereof, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1984-10-03 | — | — | EP | disclosed |
| US-4395410-A | Quaternary ammonium antiarrhythmic drugs | ELI LILLY AND COMPANY (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0002604-B1 | QUATERNARY AMMONIUM SALTS, AND THEIR FORMULATIONS AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4289787-A | PROLONG ACTION POTENTIAL OF CARDIAC TISSUE | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| EP-0002604-A1 | Quaternary ammonium salts, and their formulations and preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298097-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND | POF1B, ADH1C, OSBP | CYP4F2 57/4885CYP4A11 53/4885MAPT 4032/4885 |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | POF1B, ADH1C, OSBP | CYP4F2 57/4885CYP4A11 53/4885MAPT 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.